Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN IN DEXTROSE versus DABIGATRAN ETEXILATE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN IN DEXTROSE versus DABIGATRAN ETEXILATE MESYLATE.
ARGATROBAN IN DEXTROSE vs DABIGATRAN ETEXILATE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Argatroban is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and protein C, and platelet aggregation.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, preventing fibrinogen cleavage and clot formation.
Initial bolus of 350 mcg/kg IV over 3-5 minutes, followed by continuous IV infusion at 25 mcg/kg/min for normal coagulation; titrate to aPTT 1.5-3 times baseline, not exceeding 100 seconds; typical infusion rate 2-10 mcg/kg/min.
150 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 39–51 minutes in healthy subjects; prolonged in hepatic impairment (up to 3.1 hours). Clinically, it corrects within 2–4 hours after infusion cessation.
Terminal elimination half-life: 12–17 hours (mean ~14 hours) in healthy adults; prolonged to 15–34 hours in moderate renal impairment (CrCl 30–50 mL/min); no significant change in mild hepatic impairment. Clinical context: Supports twice-daily dosing; accumulation risk in renal impairment.
Primarily hepatobiliary (fecal excretion) ~65% as unchanged drug and metabolites; renal excretion ~22% (12% unchanged, 10% as metabolites). Minimal biliary excretion of unchanged drug.
Renal: 80% unchanged drug via glomerular filtration and tubular secretion; Fecal: ~6% via biliary secretion; Hepatic metabolism (minor) via esterase-mediated hydrolysis to glucuronide conjugates (less than 5% of dose).
Category C
Category C
Direct Thrombin Inhibitor
Direct Thrombin Inhibitor